|Nom||Titre||Payer||Exercé||Année de naissance|
|Mr. Jesus Martin-Garcia||Chairman & CEO||629,22k||S.O.||1962|
|Mr. Miguel Payró||Chief Financial Officer||S.O.||S.O.||1965|
|Dr. Hervé Perron||Chief Scientific Officer||S.O.||S.O.||1959|
|Dr. David Leppert M.D.||Chief Medical Officer||S.O.||S.O.||1958|
|Dr. Alois B. Lang Ph.D.||Chief Devel. Officer||S.O.||S.O.||1952|
GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company's lead therapeutic candidate is temelimab, a monoclonal antibody, which has completed Phase IIb clinical trial for multiple sclerosis; and is in Phase IIa to treat type 1 diabetes, as well as is in Phase I for the treatment of chronic inflammatory demyelinating polyneuropathy. It has cooperative research and development agreements with The National Institute of Neurological Disorders and Stroke to develop novel therapeutic antibodies for the treatment of amyotrophic lateral sclerosis; and Academic labs to develop inflammatory psychosis, as well as a research collaboration agreement with International Center for Infectiology Research; and with Northwestern University for human endogenous retrovirus W envelope protein (HERV-W ENV) in long-haul COVID patients. The company was incorporated in 2006 and is headquartered in Plan-les-Ouates, Switzerland.
L’ISS Governance QualityScore de GeNeuro SA en date du 1 septembre 2022 est 9. Les scores principaux sont Audit : 9; Société : 9; Droits des actionnaires : 1; Compensation : 6.